<?xml version="1.0" encoding="UTF-8"?>
<p>Remdesivir (2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl] methoxy}(phenoxy) phosphoryl] amino} propanoate) (
 <xref ref-type="fig" rid="jcm-09-02084-f005">Figure 5</xref>, see brief description in 
 <xref rid="jcm-09-02084-t002" ref-type="table">Table 2</xref>) is considered at this point the most promising treatment for SARS-CoV-2 infection on the basis of the latest outcomes acquired within the phase III clinical trials sponsored by the manufacturer [
 <xref rid="B57-jcm-09-02084" ref-type="bibr">57</xref>] and the National Institute of Allergy and Infectious Diseases (NIAID) in the Adaptive COVID-19 Treatment Trial (ACTT) [
 <xref rid="B58-jcm-09-02084" ref-type="bibr">58</xref>].
</p>
